AbbVie Announces Data From Its Phase 3 AFFIRM Study Of SKYRIZI Demonstrates 35.8% Of Patients With Crohn's Disease Achieved Endoscopic Remission After Treatment

AbbVie announced results from its Phase 3 AFFIRM study of SKYRIZI (risankizumab-rzaa) for treating moderately to severely active Crohn's disease, revealing that 35.8% of patients achieved endoscopic remission post-treatment. Additionally, 36.6% of patients with ulcers at the study's start reached ulcer-free endoscopy, with even higher rates of 45.1% and 49.0% among advanced therapy-naïve patients. These findings were presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.